Clinical Research • Clinical Trials • Pharmaceutical Industry • Biotechnology • Health Economics • Outcomes Research • Regulatory Affairs • Lifesciences • Medical Affairs • Drug Development • Pharmacovigilance • CRO • Medicine • Hematologic Malignancies • Oncology - including breast cancer, ovar... • Hematology including myelodysplastic syn... • Oncology • Clinical Development
Clinical Research Clinical Trials Pharmaceutical Industry Biotechnology Health Economics Outcomes Research Regulatory Affairs Lifesciences Medical Affairs Drug Development Pharmacovigilance CRO Medicine Hematologic Malignancies Oncology - including breast cancer, ovarian cancer, and lung cancer Hematology including myelodysplastic syndrome and myeloproliferative disorders Oncology Clinical Development
Languages:
Spanish
License Records
April H Teitelbaum
Address:
5750 Brittany Forrest Ln, San Diego, CA
10275 Science Ctr Dr, San Diego, CA
Phone:
(650)6544021
License #:
54044 - Expired
Category:
Health Care
Issued Date:
Aug 17, 1988
Effective Date:
Feb 16, 2004
Expiration Date:
Jan 31, 2002
Type:
Medical Doctor
Medicine Doctors
Dr. April H Teitelbaum, San Diego CA - MD (Doctor of Medicine)
12264 El Camino Real Suite 300, San Diego, CA 92130 (609)3692237 (Phone)
SIDHU AMARPAUL S MD OFFICE 412 W Carroll Ave Suite 210, Glendora, CA 91741 (626)3355265 (Phone), (626)3355293 (Fax)
Certifications:
Internal Medicine, 1982
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School Rush University Graduated: 1977 Medical School Los Angeles Co Hosp Graduated: 1977 Medical School Usc Med Ctr Graduated: 1977 Medical School Cedars-Sinai Med Ctr-Ucla Graduated: 1977
Erard Gilles - Bridgewater NJ, Lars-Axel Sternas - Verona NJ, Ovid Trifan - Bridgewater NJ, Helgi van de Velde - Beerse, April Teitelbaum - Doylestown PA,
Assignee:
Pharma Mar, S.A. Sociedad Unipersonal - Madrid
International Classification:
A61K 9/127 A61P 35/00 A61K 31/704 A61K 31/4995
US Classification:
424450, 514 34, 514250
Abstract:
A method of treating the human body for cancer comprises administering an effective therapeutic amount of a Pegylated Liposomal form of the anthracycline Doxorubicin (“PLD”), in combination with an effective therapeutic amount of ET-743